TBK1 and autoimmune disease: Interestingly, treatment with the USP8 inhibitor significantly reduced the protein levels of MDA5 and p‐TBK1 in PBMCs (Figure 7J,K; Figure S7C, Supporting Information), suggesting that USP8 could be a promising therapeutic target for treating MDA5‐related autoimmune diseases.